胸腺上皮肿瘤患者的手术、放疗和全身治疗:一项系统综述
该系统综述由安大略健康(癌症护理安大略)循证护理项目与肺癌疾病站点组制定,检索MEDLINE、EMBASE和Cochrane图书馆,纳入106项研究(主要为观察性研究),评估手术、放疗或全身治疗。胸腺癌和胸腺瘤患者术后放疗均有总生存获益(HR分别为0.65和0.70),胸腺癌或胸腺瘤患者对化疗有反应;文献质量低且存在偏倚,结果用于指导临床实践指南的治疗推荐。
要点
- 胸腺癌患者术后放疗与总生存获益相关(HR=0.65,95%CI:0.47-0.89)。
- 胸腺瘤患者术后放疗与总生存获益相关(HR=0.70,95%CI:0.59-0.82)。
- 胸腺癌或胸腺瘤患者对化疗有反应;文献质量低且存在偏倚,需前瞻性研究。
核心结论
- 对于胸腺瘤或胸腺癌患者,文献质量低且存在偏倚,术后放疗有总生存获益。
- 该系统综述结果用于指导临床实践指南中的治疗推荐。
- 未来需要控制混杂因素的大规模前瞻性研究。
研究设计与样本
- 本系统综述由安大略健康(癌症护理安大略)循证护理项目与肺癌疾病站点组制定。
- 检索MEDLINE、EMBASE和Cochrane图书馆,纳入比较手术、放疗或全身治疗与这些治疗任意组合的研究。
- 共纳入106项研究,主要来自观察性研究。
- 对临床同质研究进行Meta分析。
主要发现
- 胸腺癌患者术后放疗有总生存获益(HR=0.65,95%CI:0.47-0.89)。
- 胸腺瘤患者术后放疗有总生存获益(HR=0.70,95%CI:0.59-0.82),尤其对于死亡高风险患者。
- 胸腺癌或胸腺瘤患者对化疗有反应。
- 评估新辅助化疗或微创手术技术的研究结果受选择偏倚影响。
- 辅助化疗的总生存获益可能受到术后放疗实施的混杂影响。
关键数值与推荐
- 胸腺癌术后放疗总生存获益:HR=0.65(95%CI:0.47-0.89)。
- 胸腺瘤术后放疗总生存获益:HR=0.70(95%CI:0.59-0.82)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 文献质量低且存在偏倚。
- 评估新辅助化疗或微创手术技术的研究结果受选择偏倚影响。
- 辅助化疗的总生存获益可能受到术后放疗实施的混杂影响。
- 未来需要控制混杂因素的大规模前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Thymic epithelial tumors are rare and are classified as thymoma, thymic carcinoma, and thymic neuroendocrine tumors. The objective of this systematic review was to evaluate the treatment options for patients with thymic epithelial tumors. METHODS: This systematic review was developed by Ontario Health (Cancer Care Ontario)'s Program in Evidence-Based Care and by the Lung Cancer Disease Site Group. MEDLINE, EMBASE, and the Cochrane Library were searched for studies comparing surgical, radiotherapy, or systemic treatments against any combination of these treatments in patients with thymic epithelial tumors. Meta-analyses were conducted with clinically homogenous studies. RESULTS: A total of 106 studies were included, mainly from observational studies. There was an overall survival benefit with postoperative radiotherapy for patients with thymic carcinoma (hazard ratio = 0.65, 95% confidence interval: 0.47-0.89) and for patients with thymoma (hazard ratio = 0.70, 95% confidence interval: 0.59-0.82), especially for those with a high risk for mortality. Patients with thymic carcinoma or thymoma had a response to chemotherapy. Selection bias affected the results for studies that evaluated neoadjuvant chemotherapy or minimally invasive surgical techniques. Furthermore, the overall survival benefit found for adjuvant chemotherapy may have been confounded by the administration of postoperative radiotherapy. CONCLUSIONS: For patients with thymoma or thymic carcinoma, the literature is of low quality and subject to bias. There were overall survival benefits with postoperative radiotherapy. The results of this systematic review were used to inform treatment recommendations in a clinical practice guideline. Future large-scale prospective studies that control for confounders are needed.
引用
- Falkson CB, Vella ET, Ellis PM, et al. Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review. J Thorac Oncol. 2022. PMID: 36343922. doi:10.1016/j.jtho.2022.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。